Lifescience Global

JCRUV1N1A03

Image

JCRUV1N1A03

Topical Treatment of Skin Squamous Cell Carcinoma with Potassium Dobesilate Cream - Pages 10-13

Pedro Cuevas1, Javier Angulo1, Adrián Cuevas-Bourdier2 and Guillermo Giménez-Gallego3

1Departamento de Investigación, Servicio de Histología, IRYCIS; 2Servicio de Anatomía Patológica, Hospital Universitario Ramón y Cajal; 3Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain

DOI: http://dx.doi.org/10.6000/1929-2279.2012.01.01.03

Files

  • Additional Information

    Abstract: Skin squamous cell carcinoma, the second most common skin cancer arises from the malignant proliferation of keratinocytes in the epidermis. Although it is locally invasive, surgical excision or topical therapy is usually curative. However, surgical management of skin squamous cell carcinoma located in certain regions of the body may require reconstructive procedures. This can result in significant scarring and increased morbidity and dysfunction. Topical therapy may be preferable to surgery depending on anatomic localizations, and in instances where patients reject it or are poor surgical candidates. Fibroblast growth factors are variously implicated in skin tumorigenesis where they may be involved in the enhancement of tumor cell proliferation and viability, induction of angiogenesis and stimulation of tumor invasiveness. We investigated the efficacy and safety of the fibroblast growth factor inhibitor, dobesilate, administered as a 5% potassium cream, for the treatment of skin squamous cell carcinoma. Two months application of dobesilate cleared squamous cell carcinoma probably due to inhibition of cell proliferation and angiogenesis, and induction of tumor cell apoptosis. No local side effects were observed in relation with treatment. This report highlights the need for efficient and safe topical therapies in the management of skin neoplasms and supports the use of potassium dobesilate in non-melanoma skin cancers treatment.

    Keywords: Fibroblast growth factor, Fibroblast growth factor inhibitor, Topical therapy, Nonmelanoma skin cancer, STAT3

    OUR STRENGTHS

    ♦  Worldwide readership
    ♦  High quality content
    ♦  Maximum visibility
    ♦  Efficient publishing
    ♦  Optional Open Access

    Publish your Research

    Survey

    As an author what type of publishing model you prefer?

    780
    Open Access
    493
    Optional Open Access
    338
    Subscription based
    5 Votes left